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Carbohydrate chains of Cl-inhibitor wcrc iden!ified with a binding assay using different Iectins. Lectins from Surztbrtc~ r@u (SNA) and hhxkia 
rrmrrerbs (MAA) that arc specific for sialic acids bound to Cl-inhibitor. Lectin from Darrrru sfrun~oniunr (DSA) reacted also with the inhibitor 
indicating complex and hybrid sugar structures. CI-inhibitor was enzymatically desialylated and reexamined for lectin binding. SNA and MAA 
did not react anymore, but in addition to DSA. peanut agglutinin, which can bind to carbohydrate chains after sinlic acids are removed, bound 
to dcsialyloted Cl&~hibitor. Cl-inhibitor contains about 30 sialic ncid residues per molecule. SDS-polyacrylamidc gel elcctrophorcsis showed that 
desialylated Cl-inhibitor had a faster mobility than native Cl-inhibitor. The N-terminnl sequence of desialyloted Cl-inhibitor was the same as or 
native Cl-inhibilor and no change in the inhibition of human plasma kallikrein was observed. 
Cl-inhibitor; Neuramindase treatment; Sialic acid; Lectin; N-terminal sequence 
1. INTRODUCTION 
The serine proteinase inhibitor superfamily (serpins) 
consists of more than 40 homologous proteins with dif- 
ferent functions. A recent review explains some charnc- 
teristics of that family based upon the three-diniensional 
structure of the serpin member a,-proteinase inhibitor 
[l]. cz,-proteinase inhibitor, a,-antichymotrypsin, an- 
tithrombin III, and Cl-inhztiitor from human plasma 
were among the first purified members of the serpins [2]. 
These proteins function as inhibitors cf serine pro- 
teinases from which the name serpin was coined in 1985 
by Carrel1 and Travis [3]. The evolutionary relationship 
of the superfamily was earlier discovered by sequence 
comparison of ovalbumin, antithrombin III and al-pro- 
teinase inhibitor [43. 
using molecular sieve chromatography, Cl-inhibitor is 
eluted at around 200,000 Da, regardless of whether a 
Sephadex resin [6] or a TSK-HPLC column (unpub- 
lished) is used. Furthermore, 13 glycosylation sites have 
been identified [S] and there are probably more. 
In this paper we want to report some charnctcristics 
of the carbohydrate chains of the Cl-inhibitor and the 
desialylated C 1 -inhibitor. 
2. MATERIALS AND METI-IODS 
Human Cl-inl&itor was purified according to Harrison [G]. Glycan 
The Cl-inhibitor features some differences when 
compared to other serpins. Firstly, the homology to 
other serpins does not begin with the N-terminal end of 
the inhibitor but rather at residue 120 [S]. Secondly, 
although all serpins from plasma seem to be glyco- 
sylated, some data indicate that the Cl-inhibitor has a 
hiyh carbohydrate moiety. The protein consists of 478 
amino acids with a calculated molecular weight of 
52,869 Da [S], but molecular weight determination 
using a SDS- polyacrylamide gel shows an apparent 
mcllecular weight of approximately 100,000 Da and 
differentiation kit, labelled antibodies against digoxigenin, and neu- 
raminidasc were purchased from Bochringer Mannheim, Germany. 
Human plasma knllikrein and antibodies against Cl-inhibitor were 
from Mcdor, Herrsching, Germany. Substrates for kallikrein and neu- 
raminidase were bought from Sigma, Munich, Germany. Chemicals 
for HPLC runs and for protein sequencing were purchased irom 
Applied Biosystems, Weiterstadt, Germany. Rainbow markers were 
from Amersham, Braunschweig, Germany. All other reagents were 
either from Sigma or Merck, Durmstadt, Germany. 
Currcspor~dm-c udhm: O.L. Schocnbergcr, Department 01’ Molecu- 
lar Biology, Bernhard-Nocht-Institute for Tropical Medicine, 
Bernhard-Nocht-Str. 74.2000 Hamburg 36, Germany. Fax: (49) (40) 
31182 400. 
The concentration of human Cl-inhibitor wascalculated using A:kb, 
= 3.C [6]. The concentration of human plasma knllikrein was estimated 
from the amount of the protein (1 U = l/l.5 mg per vial) and a 
molecular weight of 98 kDa [73. One unit human plasma kallikrein 
(specific activity according to the mnnuhcturer: 15 Ulmg kallikrcin) 
wus dissolved in I ml 0.1 M Tris buffer, pi-l 8.3 containing 0.005% 
Triton X-100 and the activity was dctcrmined with Bz-Pro-Phe-Arg- 
pNA (0.1 mM iinal concentration) as substrate. The activity (mu) was 
calculatd from the absorbance change at 405 nm with AJuT = 8,800 
M-’ - cm-’ [S]. lnbibition of kallikrein was measured after preincu- 
bating 50 ,uI 0. I M Tris bulkr containing 0.005% Triton X-100, 50 yl 
of the dissolved human plasma ktllikrein and dil’ferent amounts of 
native and desialylated Cl-inhibitor for 30 min. The reaction W~IS 
stopped by diluting the mixture to I mi with Triu buiTtx au; ihe 
residual human plasma knllikrein activity was immediately measured. 
Neuraminidase activity was detcrminrd with N-acetylneuramine 
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lactose as substrate, To 250 ,ul 0.1 M KP, buffer, pH 50 containing 
0.1% N;, 5 ,ug neuraminidase from Closrrirhm perj%~g:ars (1 mg 
dissolved in I ml phosphate buffer) and 10 ~1 substrate (IO mg N- 
ncctylneuraminlactosdml I-I@) were added. The released sialic acid 
was determined according to Aminoff [9]. The activity of neuram- 
inidase was 0.9 yg released sialic acid/5 pug neuraminidase per min. 
Sialic acids were removed chemically from Cl-inhibitor by hydroly- 
sis with 0.1 M sulfuric acid for 90 min 31 SOOC. Ncurruninidnse treat- 
ment of Cl-inhibitor was done by incubating 3-5 mg Cl-inhibitor 
dissolved in I ml 0.1 M KPi, pi-i 5.0, containing 0. I% N; with IO-20 
yl of ncuraminidasu from Closrridilrrn perfiingurs (I mg dissolved in 
1 ml phosphate buffer) overnight at 37’C. Released sialic acids were 
quantitatively determined by taking aliquots of the reaction mixture 
and/or after separation of the sialic acids from Cl-inhibitor by gel 
filtration. 
SDS-PAGE was performed according to Laommli IlO] using a Bio- 
Had Mini Protean I1 dual slab cell. Western blots were carried out as 
described by Towbin [I I]. They were developed with digoxigenin- 
labclled lcctins and peroxidase-labelled antibodies raised against 
digoxigenin 1121. The peroxidasae activity was visualized with HzO#- 
chloro-I-naphtol, Reversed-phnsc HPLC was performed using an Aq- 
uapore RP 300 microbore column (2.1 mm x 30 mm) and a 130 A 
HPLC system (Applied Biosystems). The volume of the injection loop 
was 2 ml. To elnte the Cl-inhibitor a linear gradient running from 
0.1% TFA to 70% acctonitrile in 0.1% TFA in 45 min was applied 
immedintcly after injection. The column temperature ~3s set 3t 50°C 
and tl1e flow rate was 200,&min (with the 2 ml loop that WC used, the 
gradient actually started IO min later). Proteins were mensured at 214 
nm. Protein sequencing was done with nn Applied Biosystems 473 A 
protein scqucnccr using the program supplied by tlx manufacturer. 
Cl-inhibitors were desalted using either the above reversed-phase 
HPLC or extensive dialysis against wntcr followed by lyophilisation. 
3. RESULTS 
3.1. Types of carboltydrure chains in CI-inhibitor 
In order to investigate what types of carbohydrate 
chains are linked to Cl-inhibitor, the binding of Cl- 
inhibitor to lectins was studied in Western blots, where 
the first antibody was replaced by different lectins that 
were labelled with digoxigenin. The lectins and their 
specificity used to differentiate the types of carbohy 
drate chains in Cl-inhibitor are listed in Table I. Screen- 
Table 1 
Lectins to identify carbohydrate types of glycoproteins 
Leclin 
Gnlfmrhtrs niv& ngglutinin 
(GNA) 
Specificity 
Mannosc a( lJ)mannosc 
Mannose a( I-6)mannose 
Mnnnosc a( I-2)mannose 
(high mannose or hybrid type) 
Santbucris nigru agglutinin 
(SNA) 
Sialic acid a(2-G)galactose 
Muackiu amura~sis agglutinin 
(MAA) 
Peanut agglulinin 
(PNA) 
Daruru srrmzoniwtz ngglutinin 
(DSA) 
Sialic acid a(2-3)galactose 
Gnlactose /3( l-3) N-acetyl- 
galactoseamine 
Galactose J( 14) N-acelyl- 
giitactoseaminc 
(complex and hybrid type) 
266 
97.4 
69 
46 
36 
21.5 
I 2 3 4 5 6 
Fig. 1. Western blot analysis of Cl-inhibitor with digoxigenin-labelled 
!cctins. Lanes I, 3 and 5. fectuin; lanes 2,4 and 6. Cl-inhibitor. Lanes 
I and 2 were incubated with digoxigcnin-labclled Smburus nigru 
agglutinin, lanes 3, 4 and 5 with Muackiu unmrcnsis ngglutinin and 
hmc 6 with Dnrmw srrun~onirmr agglutinin. Molecular mass standards: 
myosin (200 kDQ, phosphorylase b (97.4 kDa), bovine serum albumin 
(69 kDa), ovalbumin (46 kDa), carbonicnnhydrase (30 kDa), soybean 
trypsin inhibitor (21.5 kDa),lysozymc (14.3 kDa). Fctuin was supplied 
with the glycan differentiation kit as control protein. 
ing of Cl-inhibitor with these lectins showed (Fig. l), 
not unexpectedly, a positive reaction with SNA and 
MAA (lanes 2 and 4), the lectins specific for sialic acids 
[13]. Besides these two lectins, the lectin DSA (lane 6) 
produced also a positive reaction indicating the pres- 
ence of complex and hybride sugar structures [13]. The 
other two lectins GNA and PNA did not bind to Cl- 
inhibitor. The negative reaction with GNA suggests the 
lack of high mannose type sugars [13]. PNA can react 
with O-glycosidic bound carbohydrates, which are pres- 
ent in Cl-inhibitor [Sj, but since siahc acids can prevent 
the binding of PNA to carbohydrate chains [13], a pos- 
itive reaction should be expected after sialic acids have 
been removed from Cl-inhibitor. 
3.2. Removed qf siuiic acids from Cl-ithibitor md their 
quarUitative determinntiorz 
In an initial experiment, Cl-inhibitor was incubated 
with different amounts of neuranainidase and the diges- 
tion was analyzed with the lectins SNA and MAA, 
which can distinguish between sialic acids linked via 
~~(2-6) or via ~~(2-3) to galact.ose (see Table I). We had 
some indication that ncuraminidase preferred the a(2- 
3) bond, because the lectin SNA still reacted with neu- 
raminidase treated Cl-inhibitor while the lectin MAA 
failed to do so. To remove all sialic acids an overnight 
incubation as described in section 2 was necessary, so 
neither MAA nor SNA gave a positive signal. The 
amount of sialic acid bound to Cl-inhibitor was deter- 
431 
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mined after separation of the released sialic acid using 
molecular sieve chromatography. 32-34 residues of 
sialic acids were bound to 1 molecule Cl-inhibitor. This 
number is slightly higher than the 26 residues of sialic 
acid found after hydrolysis of Cl-inhibitor in 0.1 M 
H2S04 for 90 min. 
3.3. Characterization of desiutylated Cl-inhibitor 
3.3.1. Binding of lectins to desialylated Cl-inhibitor 
After sialic acid has been removed the reaction of 
Cl-inhibitor with lectins (Table I) gave a different pat- 
tern. MAA (not shown) and SNA did n.ot bind to Cl- 
inhibitor anymore, DSA bound (not shown), but now 
PNA, which did not bind to the native Cl-inhibitor, 
gave a strong reaction with desialylated Cl-inhibitor 
(Fig. 2) confirming the presence of O-glycosidic linked 
sugars. 
3.3.2. Chromatography of desialylated Cl -inhibitor 
Desialylated Cl-inhibitor was applied to a reversed 
phase HPLC using a microbore column (Fig. 3B). Al- 
though negative charges have been removed and the 
desialylated Cl -inhibitor is supposed to be more hydro- 
phobic, it was eluted earlier than the native Cl -inhibitor 
97.4 k 
69 k 
46 k 
30 k I 
21.5 k 
14.3 k 
I 
II 
I 2 5 4 5 
Fig. 2. Western blot nnalysis of dcsialylntcd Cl-inhibitor with digoxi- 
gain labclled Icctinu. Lane 1, transferrin; lane 2, native Cl-inhibitor; 
iane 3, fetuin; ianes 4 and 5, desiuiyiaiicd Ci-illhibiior. iuuti i-i were 
incubatad with digodgenin-IabclLd Surrlbuc~u trigra agglutinin, lane 
5 with peanut agglutiu. Transfcrrin and fctuin were supplied with the 
&can differentiation kit as control proteins. 
Aa14 - 
42.77, 
42.36 
I 
L 
T 
0 
42.66 
I 
I 
I 
:! 
I! / 
C 
11 i 
$Jl,, 
--WA IO 20 30 40 50 60 
min 
Fig. 3. Analysis of Cl-inhibitor by reversed-phase HPLC. A, native 
Cl-inhibitor; D, desinlylnted Cl-inhibhor; C, mixture of native and 
desialylated Cl-inhibitor. 
[Fig. 3A). The retention time is only marginally faster, 
but this slight change was observed repeatedly with dif- 
feiaent preparations of Cl-inhibitor after sialic acid had 
been removed. Under the experimental conditions used, 
the injection of both inhibitors together into the column 
did not result in any separation (Fig. 3C). 
3.3.3. N-terminal characterization of desielylated 
Cl-inhibitor 
Comparison of lanes 2 and 5 in Fig. 2 shows that 
desialylated Cl-inhibitor runs faster than native. This 
behaviour was also seen when Cl-inhibitor was digested 
with various proteinases from different sources [14-171. 
In the case of digestion with human skin chymase, a new 
N terminus was detected [14]. To show that no prote- 
olylic digestion had occurred, the N-terminal seq.uences 
of native and desialylated Cl-inhibitor, respectively, 
were determined. In both cases, we obtained the known 
N-terminal amino acid sequence 0:’ C 1 -inhibitor. 
3.3.4. Inhibition of plasma kallikrein with desialylated 
Cl -inhibitor 
The inhibition of human plasma kallikrein with desia- 
lylated and with native Cl-inhibitor are shown in Fig. 
4. No difference in the inhibition ability of desialylated 
Cl-inhibitor was observed, but an exact kinetic analysis 
has not yet been performed (see section 4). 
4. DISCUSSION 
From the serpins of human plasma, only the three- 
dimensional structures of a,-proteinase inhibitor and 
a,-antichymotrypsin have been described [lS,i9]. In 
both cases the N-P’1 bond (Schechtcr and Eerger nota- 
tion [20]) of the inhibitors was cleaved which seems to 
facilitate the crystallisation of serpins. To have crystals 
of Cl-inhibitor would be of considerable interest, be- 
cause of the differences with other serpins. However, 
attempts to crystallize native Cl-inhibitor have failed so 
far (M. Bauer and W. Bode, personal communication). 
Bruch et al. [21] treated Cl-inhibitor with thermolysin 
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Inhibition of Human Plasma Kallikrein 
by Natlve and Dcslalylated Cl-lnhil~itor 
0 10 20 30 40 50 60 
Cl-l*lhCtor CPnconlr~tlon Cntl) 
Fig. 4. Humnn plasmu kallikrcin inhibition by native (m) and desiulyl- 
atcd (3) Cl-inhibitor. 
and showed with CD measurements that Cl-inhibitor 
changed its structure to a more stable cleaved form. We 
also tried to obtain modified Cl-inhibitor by thermoly- 
sin digestion. Although the SDS gel only showed two 
bands that were close together, N-terminal sequence 
analysis of the thermolysin-treated Cl -inhibitor did not 
give an unambiguous result (unpublished). 
Another reason for having difficulties to grow crys- 
tals of Cl-inhibitor might be due to its high carbohy- 
drate moiety. It is obvious that the method of choice for 
obtainiilg Cl-inhibitor without carbohydrate chains 
would be to produce recombinant (X-inhibitor ex- 
pressed in E, cofi. Earlier we used an expression system 
that was successful in the case of a,-antichymotrypsin 
[22]. Cl-inhibitor was also expressed as indicated by 
Western blot analyses, but we could not detect any in- 
hibitory activity against human plasma kallikrein 
(Rubin, I-I., Schoenberger, O.L., Wang, M., McLarney, 
S. and Cooperman, B.S., unpublished results). Thus as 
an alternative we considered removing the carbohy- 
drate chains enzymatically. 
We first screened Cl-inhibitor with lectins and 
showed that sialic acid and complex and hybrid-type 
N-linked carbohydrute chains are present, whereas 
high-mannose type carbohydrates appeared to be ab- 
sent. Nsuraminidase treatment of Cl-inhibitor removed 
all sialic acids, but we were not successful using en- 
doglycosidase H and F digestion to remove the carbo- 
hydrate chains. In a recent report [23] other endoglyco- 
sidases, namely peptid-IV-glycosidase F and O-glycosi- 
dase, were used. These enzymes seemed to have rc- 
moved a large portion of the carbohydrate chains of 
C 1 -inhibitor as indicated by SDS-gel electrophorcsis. 
However the authors did not further analyze to what 
extenl the inhibitor was deglycosylated (they were only 
able to lower the molecular weight to 65,000 Da instead 
of the expected 53,000 Da). 
Desialylated Cl-inhibitor did not differ from native 
Cl-inhibitor in that the N-terminal sequence was identi- 
cal. This showed that the faster mobility of desialylated 
Cl-inhibitor in the SDS gel was not caused by proie- 
olytic digestion. In addition to the same sequence desia- 
lylatcd Cl-inhibitor retained the inhibitory activity. Al- 
though the curves in Fig. 4 are superimposable, a small 
change in the association rate. constant for the reaction 
of kallikrcin with desialylated Cl-inhibitor might be 
possible. The second-order ate constant for the inhibi- 
tion of different proteinases with Cl-inhibitor lies be- 
tween 10’ and lo5 M-l * S-I [24-271 making the exact 
determination a complicated task, because usually only 
low amounts of the target enzymes are available. In 
addition to that, there is mounting evidence that serpins 
not only form an SDS-stable complex with their target 
enzymes, but that a relatively stable enzyme-inhibitor 
complex can occur [__,_ 73 78-301 from which the reaction 
can branch leading to a stable SDS complex and to 
inactive inhibitor [22]. It was even discussed [3 l] that the 
protease-serpin complex could be reversible as it is 
known for Kunitz-and-Ram1 type proteinase inhibitors 
[33-341. Interestingly, this mechanism was considered 
for mutant Cl-inhibitor expressed in eucaryotic COS 
cells [31]. Whether the carbohydrate part of Cl-inhibi- 
tor influences the inhibition mechanism and the rate 
constant will be analyzed when, in addition to desia- 
lylated Cl-inhibitor, deglycosyiatcd Cl-inhibitor is 
available. 
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